In this study, we determined the in vitro and in vivo efficacy of sodium iodide symporter (NIS) gene transfer and the therapeutic potential of oncolytic virotherapy combined with radioiodine therapy using a conditionally replicating oncolytic adenovirus. For this purpose, we used a replication-selective adenovirus in which the E1a gene is driven by the mouse alpha-fetoprotein (AFP) promoter and the human NIS gene is inserted in the E3 region (Ad5-E1/AFP-E3/NIS). Human hepatocellular carcinoma cells (HuH7) infected with Ad5-E1/AFP-E3/NIS concentrated radioiodine at a level that was sufficiently high for a therapeutic effect in vitro. In vivo experiments demonstrated that 3 days after intratumoral (i.t.) injection of Ad5-E1/AFP-E3/NIS HuH7 xenograft tumors accumulated approximately 25% ID g À 1 (percentage of the injected dose per gram tumor tissue) 123 I as shown by 123 I gamma camera imaging. A single i.t. injection of Ad5-E1/AFP-E3/NIS (virotherapy) resulted in a significant reduction of tumor growth and prolonged survival, as compared with injection of saline. Combination of oncolytic virotherapy with radioiodine treatment (radiovirotherapy) led to an additional reduction of tumor growth that resulted in markedly improved survival as compared with virotherapy alone. In conclusion, local in vivo NIS gene transfer using a replication-selective oncolytic adenovirus is able to induce a significant therapeutic effect, which can be enhanced by additional 131 I application.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer worldwide and the third leading cause of cancer deaths in the world with an increasing incidence in the western world. 1, 2 Owing to limited response to conventional radio-or chemotherapy, surgery including partial hepatectomy or liver transplantation is the only potentially curative therapy that is currently available. Despite the development of various alternative therapeutic options, such as kinase inhibitors, the prognosis of patients suffering from advanced HCC is still poor. 3 Consequently, the development of novel therapeutic strategies is indispensable.
The sodium iodide symporter (NIS) is an intrinsic transmembrane glycoprotein that mediates the uptake of iodide into thyroid follicular cells. 4, 5 Owing to its expression in differentiated thyroid cancer cells, NIS represents the molecular basis for the diagnostic and therapeutic application of radioiodine, which has been successfully used for over 70 years in the treatment of thyroid cancer patients. In the last 15 years, NIS has been identified as a novel promising therapeutic gene for the treatment of extrathyroidal tumors by directed NIS gene transfer into tumor cells followed by diagnostic and therapeutic application of radioiodine. The capacity of the NIS gene to induce radioiodine accumulation in non-thyroidal tumors has been investigated in a variety of tumor models by several groups including our own. [6] [7] [8] [9] [10] [11] [12] These data clearly demonstrate the potential of NIS as a novel reporter and therapy gene for the treatment of extrathyroidal tumors.
To ensure tumor specificity of radiation exposure, the application of tumor-specific promoters offers the ability to transcriptionally target NIS gene expression exclusively to tumor cells. Alphafetoprotein (AFP) is only expressed in the yolk sac and liver of mammals during embryonic development and nearly disappears after birth. Reinitiation of AFP expression during neoplastic transformation in HCCs and teratocarcinomas provides us with a well characterized and frequently used tumor marker. 13, 14 Owing to its high specificity, the AFP promoter is an ideal tool for transcriptional targeting of gene delivery for the treatment of HCCs. 15 This study was developed as a result of the successful induction of tumor-specific iodide uptake activity in a xenograft mouse model of HCC (HepG2) after local infection with a replicationdeficient adenovirus carrying the human NIS gene linked to the mouse AFP promoter. 16 With the goal of a possible future systemic application, as a next step we aimed at extending this promising technique to a replication-selective oncolytic adenovirus using the same AFP promoter construct for transcriptional targeting of NIS expression. The use of genetically engineered replicationcompetent adenoviruses has emerged as a powerful approach for increasing transduction efficiency and therapeutic efficacy by an additional oncolytic effect because of cancer-selective virus replication. We therefore examined the feasibility of oncolytic virotherapy following replication-selective adenovirus-mediated human NIS gene transfer in a HCC xenograft mouse model. In the newly developed Ad5-E1/AFP-E3/NIS construct the E1a gene, which is essential for viral replication, is driven by the HCC-specific AFP promoter resulting in tumor-specific replication. As the NIS gene is inserted in the E3 region under control of the replicationdependent E3 promoter, NIS expression only occurs in HCC cells, where adenoviral replication takes place. We further evaluated, if tumor-specific NIS expression allows for enhancement of the therapeutic effect of virus-mediated oncolysis through additional radioiodine therapy (radiovirotherapy).
RESULTS

Iodide uptake studies in vitro
Transduction conditions using Ad5-E1/AFP-E3/NIS were optimized in HuH7 cells by measurement of perchlorate-sensitive iodide uptake activity. At a dose of 25 multiplicity of infection (MOI), we achieved highest transduction efficiency at low cytotoxicity, which was used for all subsequent in vitro experiments (data not shown). The perchlorate-sensitive iodide uptake activity was measured at various time points after Ad5-E1/AFP-E3/NIS infection ( Figure 1a) . Maximum iodide uptake activity was observed 3 days following infection, when cells showed a 79-fold increase in perchloratesensitive 125 I accumulation as compared with HuH7 cells infected with the control virus (Ad5-control) (***Po0.001; Figure 1a ). Tumor specificity of Ad5-E1/AFP-E3/NIS was confirmed by infection of control cancer cell lines (FTC-133, 1205 Lu) not expressing AFP showing lack of perchlorate-sensitive iodide uptake activity (Figure 1b) .
Analysis of tissue-selective viral replication in vitro
Quantitative real-time PCR (qPCR) analysis revealed a strong nearly 50 000-fold increase in fiber DNA level in HuH7 cells 3 days after infection with 25 MOI Ad5-E1/AFP-E3/NIS as compared with infection of AFP-negative control cells or HuH7 cells infected with the replication-deficient Ad5-AFP/NIS, which showed no significant increase in fiber DNA level (***Po0.001; Figure 2a ). Induction of cytopathic effect (CPE) To investigate whether Ad5-E1/AFP-E3/NIS and Ad5-AFP/NIS induce CPE in HCC and control cell lines, a CPE assay was performed. As shown in Figure 2b , Ad5-E1/AFP-E3/NIS caused strong cytolysis of infected HuH7 cells at day 4 in a dosedependent manner (upper panel). In contrast, no CPE could be detected in Ad5-E1/AFP-E3/NIS-infected AFP-negative FTC-133 control cells (lower panel) or in HuH7 cells after infection with the replication-deficient Ad5-AFP/NIS virus.
In vitro clonogenic assay To evaluate the therapeutic potential of 131 I in hepatoma cells (HuH7) after Ad5-E1/AFP-E3/NIS-mediated NIS gene transfer in vitro, a clonogenic assay was performed at increasing doses (7.4, 14.8 and 29.6 MBq) of 131 I (Figure 3 ). In all, 100% of uninfected hepatoma cells survived the exposure to 29.6 MBq 131 I, whereas up to 90% of Ad5-E1/AFP-E3/NIS-infected hepatoma cells were killed by the treatment with 131 I in a dose-dependent manner (***Po0.001). Without radioiodine treatment, uninfected hepatoma cells showed survival rates comparable to those of Ad5-E1/ AFP-E3/NIS-infected cells 48 h after infection. This indicates that at this time point no major cell lysis has occurred and therefore survival of the cells was not dependent on viral infection in this experimental setup.
Radioiodine uptake studies after local in vivo NIS gene transfer Radioiodine biodistribution was monitored in tumor bearing mice on days 3, 4 and 7 after intratumoral (i.t.) injection of 5 Â 10 8 plaque-forming unit (PFU) (1.83 Â 10 10 virus particles) Ad5-E1/AFP-E3/NIS using a gamma camera to determine propagation of the virus and the peak of adenoviral spread by in vivo imaging of NIS expression. Highest transduction efficiency was observed 3 days after single i.t. injection of the replication-selective adenovirus (Figure 4a ). Thus, all following imaging experiments were carried out 3 days after adenoviral infection.
Although no specific radioiodide accumulation was detected in HuH7 tumors after infection with Ad5-control (Figure 4b ), Ad5-E1/ AFP-E3/NIS-infected HuH7 tumors (Figure 4a ) showed a significant time-dependent uptake of 123 I with a maximum at 3 days after virus injection. As determined by serial scanning, 25% ID g (Figure 4a) . Considering a tumor mass of 1 g and an effective half-life of 3.6 h for 131 I, a tumor-absorbed dose of 126 mGy MBq À 1 was calculated. In addition to tumoral uptake, significant radioiodide accumulation was observed in tissues physiologically expressing NIS, including stomach and thyroid, and tissues involved in iodide elimination (bladder).
To confirm that tumoral iodide uptake was indeed NIS mediated, Ad5-E1/AFP-E3/NIS-injected mice were additionally treated with the competitive NIS-inhibitor sodium perchlorate (NaClO 4 ) 30 min before 123 I administration, which completely blocked tumoral iodide accumulation in addition to the physiological NIS-mediated iodide uptake in stomach and thyroid gland (Figure 4c ). Furthermore, hepatoma-specificity of Ad5-E1/AFP-E3/ NIS was confirmed by infection of control tumor xenografts (FTC-133, 1205 Lu), which did not result in tumoral iodide uptake activity (Figures 4d and e) .
Analysis of NIS mRNA expression in HuH7 xenografts
The mRNA of tumors was analyzed for the level of NIS mRNA expression after i.t. Ad5-E1/AFP-E3/NIS-mediated NIS gene transfer in vivo by qPCR ( Figure 5 ). A 29-fold increase in NIS mRNA expression of HuH7 xenografts was detected 72 h after i.t. injection of Ad5-E1/AFP-E3/NIS (***Po0.001). In contrast, no significant NIS mRNA expression above background level was observed in untreated tumors or in tumors treated with the control adenovirus (Ad5-control). Figure 6b ). Although all mice in the control group had to be killed within the first 3 weeks after onset of the experiments because of excessive tumor growth, 92% of mice treated twice with 131 I after local in vivo NIS gene transfer survived approximately 7-8 weeks (Figure 6b ). Taken together, these results indicate that the combination of radiotherapy and cytolytic virotherapy was significantly superior to virotherapy alone (***Po0.001). No mouse showed major adverse effects after virus or radionuclide administration in terms of body weight loss, lethargy or respiratory failure.
Radionuclide therapy study in vivo
Immunohistochemical analysis of NIS protein expression in HuH7 xenografts Three days after the start of treatment, mice were killed and HuH7 xenografts were dissected and processed for immunohistochemical analysis using a hNIS-specific antibody (red). Analysis revealed a patchy staining pattern with areas of NIS-specific immuno-reactivity in tumors after i.t. application of Ad5-E1/AFP-E3/NIS (Figure 6c ). In contrast, tumors treated with saline only (NaCl-control) showed no NIS-specific immunoreactivity ( Figure 6d ). Parallel control slides with the primary and secondary antibodies replaced in turn by phosphate-buffered saline and isotype-matched non-immune immunoglobulin were negative (data not shown). Immunofluorescence analysis Eight days after the start of treatment, mice were killed and tumors were dissected and processed for immunofluorescence analysis using a Ki67-specific antibody (green) and an antibody against CD31 (red, labeling blood vessels; 
DISCUSSION
Our previous work in various tumor models has convincingly demonstrated the high efficacy of radionuclide therapy after tumor-selective NIS gene delivery. 10, 11, [16] [17] [18] [19] [20] In its dual role as reporter and therapy gene, NIS allows direct, non-invasive imaging of functional NIS expression by 123 I-scintigraphy, 123 I-SPECTimaging or 124 I-PET-imaging, as well as exact dosimetric calculations before proceeding to therapeutic application of 131 I or alternative radionuclides. 6, 21, 22 Tissue-specific promoters may serve as targeting mechanisms for gene expression and have been described to mediate tissuespecific expression, also in the context of NIS gene therapy of different types of cancer, thereby introducing cancer specificity for improved safety and efficacy. 7, 8, 16, 19, 20, [23] [24] [25] [26] [27] In previous studies, we already reported hepatoma-specific NIS expression after application of the AFP promoter. 16, 27 To target NIS gene expression to HCC cells, we applied a 2666 bp mouse AFP promoter construct consisting of the basal promoter and enhancer I element that already proved maximal tissue specificity and promoter activity. 27, 28 Species C adenoviruses are some of the best-studied viruses and most frequently used for oncolytic vectors. 29 The antitumor efficacy described for oncolytic adenoviruses is promising and they have been reported to be remarkably safe in animals in efficacy studies, with no significant toxicity reported. 30, 31 A replication-deficient adenovirus vector carrying the NIS gene under control of the hepatoma-specific AFP promoter was able to induce tumor-specific functional NIS expression in AFP-positive HCC cells, which was sufficiently high to allow a cytoreductive response to accumulated 131 I in vitro as well as in vivo after local application. As a next crucial step toward clinical application we have now explored the combination of the two approaches of targeted oncolytic virotherapy and NIS-mediated radiotherapy to further increase transduction efficiency and therapeutic efficacy. In this study, we therefore designed a replication-selective adenovirus Ad5-E1/AFP-E3/NIS carrying the NIS gene under the control of the same AFP promoter fragment that already proved high activity and tumor specificity in our former studies. 16, 27 A prerequisite for functional activity of the NIS protein is its proper targeting to the cell membrane. 32 This functional membrane-associated NIS protein expression after replication-selective adenoviral NIS gene transfer was confirmed by measurement of in vitro radioiodine uptake, which showed high transduction efficiency and tumor selectivity of Ad5-E1/AFP-E3/NIS with maximal transduction efficiency 72 h after virus application. The ability to concentrate high levels of radioiodine resulted in a significant therapeutic effect of 131 I in hepatoma cells in vitro which was confirmed by a clonogenic assay, performed with increasing doses of 131 I. Studies by Ma et al. 33 and Klutz et al. 16 previously reported efficient and specific cell killing of hepatoma cells in vitro using a NISexpressing replication-deficient adenovirus under control of the AFP promoter combined with 131 I treatment. We have further investigated application of the Ad5-E1/AFP-E3/ NIS virus construct for in vivo delivery of the NIS gene in HCC xenografts. NIS as novel reporter and suicide gene offers the possibility of non-invasive monitoring of NIS expression by radioiodine imaging and thereby allows exact planning of the NIS gene therapy approach. 22 The timing of administration of the therapeutic radionuclide after oncolytic virus-mediated NIS gene transfer is crucial to improve therapeutic efficacy. [34] [35] [36] In this context, molecular imaging of the level of Ad5-E1/AFP-E3/NIS-mediated NIS expression over time before administration of the therapeutic radionuclide provides essential information on the time point of maximal NIS expression and is a prerequisite for an optimized combination therapy strategy. 34 In these in vivo imaging experiments, HuH7 cell xenografts showed highest NIS expression 72 h after oncolytic virus administration. Other studies that used NIS-expressing replication-selective adenoviral vectors revealed comparable results and showed the peak of tumoral NIS expression to be 3 to 4 days after i.t. injection of the adenovirus. 26, 37 At 72 h following i.t. injection of the replication-selective Ad5-E1/AFP-E3/NIS, tumor-specific 123 I accumulation of approximately 25% ID g À 1 with an effective half-life of 5.5 h was observed resulting in a tumor-absorbed dose of 126 mGy MBq À 1 131 I. In comparison, in our former study using a replication-deficient adenovirus carrying the NIS gene under control of the AFP promoter (Ad5-AFP/NIS) HepG2 xenografts accumulated approximately 14.5% ID g À 1 123 I with an effective half-life of 13 h and a tumor-absorbed dose of 318 mGy MBq À 1 131 I was calculated. 16 Although we accumulated a higher amount of radioiodine the resulting tumor-absorbed dose in this study is lower, which is mainly due to the shorter half-life of the tumoral 123 I accumulation. A possible reason might be differences in virus dissemination and NIS expression patterns because of the oncolytic activity of the replication-selective adenovirus used in this study. A further explanation might be differences in tumor biology as different HCC cell lines were used in both studies.
Therapy studies after i.t. injection of Ad5-E1/AFP-E3/NIS in HuH7 xenografts resulted in distinct oncolytic activity leading to a significant delay of tumor growth associated with significantly prolonged survival as compared with the saline-treated control group. Despite the distinct effect of Ad5-E1/AFP-E3/NIS for oncolytic virotherapy and promising results from other studies, selectively replicating viruses, when used as single agents, may have limited efficacy primarily due to limited viral spread in the tumor. 31 The oncolytic effect can be further enhanced by simultaneous expression of therapeutic genes, for example, the NIS gene allowing for additional radionuclide therapy of tumor tissue. Radiation therapy causes damage to cellular proteins and nucleic acids leading to cell death. 38 Adenoviruses are particularly attractive as carrier of the NIS gene for radiotherapy because adenoviruses themselves act as radiosensitizers through their natural functions. 39, 40 Conversely, delivery of ionizing radiation to the tumor site has been shown to create an environment that is more sensitive to adenoviral transduction and replication, which might enhance transduction efficiency and oncolytic activity. [41] [42] [43] In fact, clinical trials have shown improved results when combining virus vectors with radiotherapy. 44 Moreover, NISmediated radionuclide therapy is associated with a substantial bystander effect, based on the crossfire-effect of the b-emitter 131 I with a path length of up to 2.4 mm, thereby compensating limited viral spread in the tumor and reducing the level of transduction efficiency required for a therapeutic response. 45 In its wellcharacterized dual function as reporter gene as well as therapy gene associated with a significant bystander effect, NIS represents an ideal candidate gene for replication-selective adenovirusmediated gene-virotherapy, providing the potential of noninvasive whole-body monitoring of in vivo biodistribution and kinetics of virus replication in addition to image-guided radiotherapy combined with oncolytic virotherapy.
In this study, i.t. injection of the replication-selective Ad5-E1/ AFP-E3/NIS led to a significant delay in tumor growth because of a distinct oncolytic effect. Moreover, local Ad5-E1/AFP-E3/NISmediated NIS gene transfer resulted in tumor-specific iodide uptake activity, which was sufficiently high for a significant therapeutic effect of 131 I additional to oncolysis. Combination of oncolytic virotherapy with radioiodine treatment resulted in a further decrease in tumor growth as well as prolongation of survival. As discussed above, monitoring of tumoral radioiodine accumulation displayed highest uptake activity 3 days after local virus administration with slowly decreasing levels of NIS expression within time. Therefore, we tested the feasibility and the impact of repeated administration of 131 I on days 3 and 5 after a single i.t. injection of the replication-selective adenovirus for combination therapy. Two injections of radioiodine after the single administration of Ad5-E1/AFP-E3/NIS further decelerated tumor growth and improved survival. These data are consistent with previous radiovirotherapy studies in different tumor models showing higher therapeutic efficacy of oncolytic virotherapy when combined with NIS-mediated radiotherapy. 26, 35, 36, 46 Penheiter et al. 34 observed a trend toward decreased tumor volume and increased mouse survival, but no complete eradication, with no significant benefit of 131 I radiovirotherapy over virotherapy alone using a NIS-encoding measles virus. This study demonstrated that appropriate timing of 131 I administration after viral infection and the best possible i.t. vector distribution are critical factors for efficient radiovirotherapy of tumor xenografts.
In this study, we used a therapeutic dose of 55.5 MBq 131 I to be able to compare the results with our earlier studies after in vivo NIS gene transfer in xenograft mouse models. 10, 11, 16, 18, 27, 47, 48 Initially, this dose was empirically tested in stably NIS-expressing xenograft tumor models and chosen in consideration of radiation safety, tolerability as well as accordance with animal protection laws. Based on our dosimetric calculations, a total tumor-absorbed dose of approximately 7 Gy was achieved, which is less than the generally assumed target dose of 80 Gy needed for a therapeutic effect in lymph node metastases according to Maxon et al., 49 but it is in the range of target doses reported for 131 I therapy in thyroid cancer patients (0.5-288 Gy per lesion) 50, 51 and was clearly high enough for a significant therapeutic effect of 131 I in addition to the oncolytic effect in our presented study. In an attempt to transfer these dosimetric calculations to humans, we would reach a tumorabsorbed dose of approximately 93.3 Gy after therapeutic application of 7.4 GBq (200 mCi) 131 I, a dose generally applied to patients with thyroid cancer metastases. In comparison, a recent clinical trial quantified the volume and magnitude of hNIS gene expression in human prostate cancers following local injection of a high dose of a NIS-expressing oncolytic adenovirus, and estimated the radiation dose that would be delivered to the prostate after 131 I administration with curative intent. 52 Assuming a standard radiation dose of 7.4 GBq (200 mCi) 131 I, the mean absorbed dose to the prostate was calculated to be only 7.2±4.8 Gy (range 2.1-13.3 Gy). Differences in the cancer entity, the experimental approach as well as adenovirus engineering might explain this pronounced discrepancy.
Inefficient i.t. viral spread limits the therapeutic effect by reduction of oncolytic cell killing as well as hampered effectiveness of radioiodine treatment. Although this is partially compensated by the crossfire effect of the b-emitting 131 I, it could be the therapy-limiting factor in this study, in which therapy with Ad5-E1/ AFP-E3/NIS slowed the progression of HuH7 xenografts, but did not lead to complete ablation of the tumors except in two mice in group radiovirotherapy 2 that had complete tumor regression up to 100 days after onset of the experiment. In addition, immunofluorescence analysis showed markedly reduced proliferation associated with decreased tumoral blood vessel density after local adenovirus-mediated NIS gene transfer followed by 131 I application, suggesting oncolytic efficacy and radiation-induced tumor stromal cell damage in addition to tumor cell death. The crossfire effect of 131 I might be responsible for stromal cell damage leading to reduced angiogenesis and secretion of growth-stimulatory factors, thereby enhancing therapeutic efficacy. However, it has been proven that virotherapeutics not only show anticancer effect by their direct oncolytic effect, but are also able to elicit a tumor-specific immune response, thereby breaking tumor tolerance. 53 To address this aspect, we are currently planning future studies using NIS-expressing oncolytic adenoviruses in an immunocompetent mouse model.
In conclusion, our data clearly demonstrate that tumor-specific NIS gene transfer using a replication-selective adenoviral gene delivery vector allows for targeted NIS-mediated, imaging-guided radionuclide therapy of extrathyroidal tumors, which enhances the therapeutic effect of oncolytic virotherapy and proves its potential use for clinical application. 
MATERIALS AND METHODS
Recombinant replication-selective adenovirus production
The human NIS complementary DNA (kindly provided by Sissy M Jhiang, Ohio State University, Columbus, OH, USA) was cloned into the shuttle vector (pVQAd-AscI-NpA) and linked to the mouse AFP promoter/enhancer I fragment (kindly provided by M Geissler, Esslingen, Germany) using KpnI and XhoI. A replication-competent human recombinant type 5 adenovirus (Ad5-E3) carrying the human NIS gene linked to the mAFP basal promoter/ enhancer element I (Ad5-E1/AFP-E3/NIS) was developed by ViraQuest Inc. (North Liberty, IA, USA). As control, a replication-deficient adenovirus carrying the NIS complementary DNA under the control of the tumorspecific AFP promoter (Ad5-AFP/NIS), generated as described previously, was used. 16 As further control an empty adenovirus (Ad5-control) was used.
Adenovirus-mediated NIS gene delivery in vitro Plates were slightly shaken every 15 min to ensure an equal distribution of the virus. Medium was replaced by fresh culture medium and virusinfected cells were further maintained for up to 4 days, before iodide accumulation was measured (see below) to determine levels of functional NIS protein expression.
125
I uptake studies in vitro
Following infection with Ad5-E1/AFP-E3/NIS or Ad5-control, iodide uptake of HuH7 or control cells was determined at steady-state conditions as described previously. 23, 54 Results were normalized to cell viability and expressed as counts per minute/A 490 nm.
CPE assay
HuH7 or FTC-133 cells were seeded in 12-well plates (1.5 Â 10 5 per well). Cells were infected with increasing doses (0, 1, 5, 10, 25 and 50 MOI) for 45 min with replication-selective Ad5-E1/AFP-E3/NIS or replication-deficient Ad5-AFP/NIS. Cells were fixed after 4 days with 10% trichloroacetic acid over night at 4 1C and stained with 0.5% sulforhodamine B (SigmaAldrich, Darmstadt, Germany) in 1% acetic acid. Quantification was done by photometric measurement at 590 nm after dissolving dried sulforhodamine B with 10 mM tris buffer at pH 8.
Cell viability assay
Cell viability was measured using the commercially available MTS-assay (Promega Corp., Mannheim, Germany) according to the manufacturer's recommendations as described previously. 55 Analysis of NIS mRNA expression and fiber DNA level using qPCR After infection with 25 MOI, Ad5-E1/AFP-E3/NIS or Ad5-control total RNA was isolated from HuH7 xenografts using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's recommendations. The level of NIS mRNA was analyzed via qPCR as described previously. 10 After infection with Ad5-E1/AFP-E3/NIS or Ad5-AFP/NIS total DNA was isolated from HuH7 and FTC-133 cells using the QIAamp DNA Mini Kit (Qiagen) according to the manufacturer's recommendations. qPCR was performed with 100 ng DNA using the SYBR green PCR master mix 
Establishment of HuH7 xenografts
HuH7, FTC-133 and 1205 Lu xenografts were established in 5-week-old female CD-1 nu/nu mice (Charles River, Sulzfeld, Germany) by subcutaneous injection of 5 Â 10 6 HuH7, 1.5 Â 10 6 FTC-133 or 5 Â 10 6 1205 Lu cells suspended in 100 ml phosphate-buffered saline into the flank region. Animals were maintained under specific pathogen-free conditions with access to mouse chow and water ad libitum. The experimental protocol was approved by the regional governmental commission for animals (Regierung von Oberbayern, Munich, Germany).
In vivo NIS gene transfer in HuH7 xenografts
Experiments started when tumors had reached a size of 5-6 mm. After a 10-day pre-treatment with L-T4 (L-thyroxin Henning, Sanofi-Aventis, Frankfurt, Germany; 5 mg l À 1 ) in their drinking water to reduce radioiodide uptake by the thyroid gland, animals were anesthetized with ketamin (Hameln Pharmaceuticals, Hameln, Germany; 100 mg g ). Thereafter, 5 Â 10 8 PFU (1.83 Â 10 10 virus particles), diluted with phosphate-buffered saline to a total volume of 100 ml) of the recombinant Ad5-E1/AFP-E3/NIS were injected at different injection sites directly into the tumor using tuberculin syringes with a 30-gauge Â 0.5-inch needle. The needle was moved to various sites within the tumor during injection to maximize the area of virus exposure.
Radioiodine uptake studies in vivo after local NIS gene transfer On days 3, 4 and 7 after i.t. injection of Ad5-E1/AFP-E3/NIS or Ad5-control mice received 18.5 MBq 123 I i.p. and radioiodine distribution was monitored by serial imaging on a gamma camera (Forte, ADAC Laboratories, Milpitas, CA, USA) equipped with a VXHR (ultra-high resolution) collimator as described previously. 48 The control mice were injected i.p. with 2 mg of the competitive NIS-inhibitor sodium perchlorate 30 min before 123 I administration. Regions of interest were quantified and expressed as a fraction of the total amount of applied radionuclide per gram tumor tissue. The retention time within the tumor was determined by serial scanning after radioiodine injection, and dosimetric calculations were performed according to the concept of MIRD, with the dosis factor of RADAR-group (www.doseinfo-radar.com).
Radionuclide therapy study in vivo
Subcutaneous HuH7 xenografts were established in four groups of mice as described above. When tumors reached about 5-6 mm in diameter, one group of mice was used as saline-injected control (NaCl-control, n ¼ 12), a second group received a single i. I each on day 3 and 5 after virus administration (radiovirotherapy 2, n ¼ 12). Tumor measurements started at the day of virus administration and were performed twice weekly thereafter, tumor volume was estimated using the equation: tumor volume ¼ length Â width Â height Â 0.52. Mice were followed for a total of 100 days or until tumor burden was such that animals had to be killed. The end point event was set at tumor burdenX1500 mm 3 .
Immunohistochemical analysis of NIS protein expression
Immunohistochemical staining of paraffin-embedded tissue sections derived from HuH7 tumors after adenovirus-mediated gene delivery was performed using a mouse monoclonal antibody directed against aminoacid residues 468-643 of human NIS (kindly provided by John C Morris, Mayo Clinic, Rochester, MN, USA) as described previously. 19 For histological examination, parallel slides were also routinely stained with hematoxylin and eosin.
Indirect immunofluorescence assay
Indirect immunofluorescence staining was performed on frozen tissues using an antibody against human Ki67 (Abcam, Cambridge, UK) and an antibody against mouse CD31 (BD Pharmingen, Heidelberg, Germany) as described previously. 48 
Statistical methods
All in vitro experiments were carried out in triplicate. Results are represented as means±s.d. of triplicates. Statistical significance was tested using Student's t-test. Statistical significance of survival curves was tested using log-rank test.
